Filing search / Cellectar Biosciences, Inc. / "Access" / Page 4

424B4

q1kyww3

4 Jun 20

Prospectus supplement with pricing info

12:00am

8-K

EX-10.1

9icxo

7 Jan 20

Cellectar Appoints Dr. Igor Grachev as Chief Medical Officer

4:01pm

8-K

EX-10.1

1wss75b9f

15 Aug 19

Cellectar Appoints Dov Elefant as Chief Financial Officer

8:30am

8-K

EX-99.1

q84e18zt3gpybm

21 May 19

Cellectar Expands Third Cohort of its Phase 2 CLOVER-1 Study of CLR 131

4:20pm

8-K

EX-10.3

e5aej2q r31xhq

20 May 19

Cellectar Biosciences Announces Closing of $10.0 Million Financing

5:30pm

8-K

EX-99.1

cz7l i61b

20 May 19

Cellectar Biosciences Announces Closing of $10.0 Million Financing

5:30pm

8-K

EX-10.2

xear011yy

20 May 19

Cellectar Biosciences Announces Closing of $10.0 Million Financing

5:30pm

8-K

EX-10.1

7yn0jw3m

20 May 19

Cellectar Biosciences Announces Closing of $10.0 Million Financing

5:30pm

424B5

m5wugb2oak4u6phlu

17 May 19

Prospectus supplement for primary offering

5:24pm

8-K

EX-99.1

gw04m07mww34 stt

16 May 19

Cellectar Biosciences Announces $10.0 Million Financing

9:01am

8-K

EX-99.1

vsik6gha 1il

15 May 19

CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma

4:21pm